)
)
Immunome Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Immunome Inc
Access all reports
Immunome, Inc. is a biotechnology company focused on developing targeted cancer therapies. The company leverages a proprietary discovery platform to identify novel antigens and develop corresponding therapies, particularly in the field of oncology. Immunome's product pipeline includes several candidates, such as AL102, a gamma secretase inhibitor currently in Phase 3 trials for the treatment of desmoid tumors, and other preclinical assets aimed at targeting specific cancer markers through various therapeutic approaches, including antibody-drug conjugates (ADCs) and radioligand therapies. The company is headquartered in Bothell, Washington, and its shares are listed on the NASDAQ.
Latest articles
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
)
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
IMNM
Country
🇺🇸 United States